NasdaqGM:ANIPPharmaceuticals
ANI Pharmaceuticals Expands Limited Competition Portfolio With New Cardiovascular Generic
ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP) has launched Isosorbide Mononitrate Tablets following final FDA approval.
The product adds a new limited competition generic to the company’s portfolio of prescription pharmaceuticals.
This launch expands ANI Pharmaceuticals' presence in generic cardiovascular treatments and broadens its revenue base.
For you as an investor, the key point is that ANI Pharmaceuticals focuses on niche and limited competition generics, alongside specialty branded...